UBS analyst Kevin Caliendo raised the firm’s price target on CVS Health (CVS) to $97 from $96 and keeps a Buy rating on the shares. The current EPS compound annual growth rate of mid-teens growth through 2028E does not contemplate any meaningful capital deployment, suggesting that CVS could have a positive upside/downside skew to earnings for 2027 and beyond, the analyst tells investors in a research note. UBS remains optimistic that Q4 has potentially more upside to EPS.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health: Strong Financial Outlook and Strategic Initiatives Drive Buy Rating
- CVS Health’s Promising Growth Trajectory and Strategic Focus Drive Buy Rating
- CVS Health: Strategic Initiatives and Financial Outlook Drive Buy Rating
- CVS Health: Projected Growth and Strategic Capital Deployment Drive Buy Rating
- Midday Fly By: Nvidia can ship H200s to China, Campbell’s reports Q1 beat